Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735612 | 0.89 | ALDH1A1 (0.54) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL2021481 | 0.88 | BCAT2 (0.46) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL3379979 | 0.86 | BCAT2 (0.44) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL30177551 | 0.85 | ALDH1A1 (0.50) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL31054164 | 0.83 | MAPT (0.48) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL731621 | 0.83 | HMGB1 (0.55) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL619877 | 0.83 | ALDH1A1 (0.52) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL7618622 | 0.83 | FOLH1 (0.48) | ALDH1A1KDM4EMAPTHPGDTSHR | |
| SCHEMBL29948180 | 0.82 | SIRT1 (0.43) | BCAT2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL2294517 | 0.82 | SIRT1 (0.43) | BCAT2ALDH1A1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240193-A | Preparation method of recyclable N-acylated polyaminoester | 苏州大学 | 2024-06-25 | — | — | CN | claimed |
| CN-110903210-A | Preparation method of organic intermediate N, N-bis (β -hydroxyethyl) benzamide | 江苏鑫露化工新材料有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-102712620-B | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN LA ROCHE | 2014-02-26 | — | — | CN | claimed |
| CN-103153945-A | 1-oximino-3-phenyl-propanes | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | claimed |
| EP-2419423-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | Cellzome Limited (GB) | 2012-02-22 | — | — | EP | claimed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1928879-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Brystol-Myers Squibb Company (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | claimed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| US-6458865-B2 | FOR DENTAL RESTORATION MATERIAL | CURATORS OF THE UNIVERSITY OF MISSOURI | 2002-10-01 | — | — | US | claimed |
| CN-118240193-A | Preparation method of recyclable N-acylated polyaminoester | 苏州大学 | 2024-06-25 | — | — | CN | disclosed |
| EP-4120837-B1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 2-(3-PHENYLUREIDO)BENZAMIDE, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024007722-A1 | PHARMACEUTICAL COMPOSITION, METHODS OF USE THEREOF FOR TREATING COCAINE ADDICTION, AND NOVEL USE OF HAUSP K444R POINT MUTANT MOUSE | PHARWARD BIOTECHNOLOGY, INC. PTE. LTD. (SG) | 2024-01-11 | — | — | WO | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1339702-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2001068619-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | BCAT2 1264/4885ALDH1A1 1236/4885KDM4E 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.